Generated by All in One SEO v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.

# TTC Oncology

TTC oncology-Innovating Safer Solutions for the Treatment of Metastatic Breast Cancer

## Sitemaps

- [XML Sitemap](https://ttconcology.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Blog](https://ttconcology.com/blog/)
- [Hello world!](https://ttconcology.com/2021/03/hello-world/) - Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

## Pages

- [](https://ttconcology.com/) - Innovating Safer Solutions for the Treatment of Metastatic Breast Cancer TTC Oncology LLC was founded in July 2015. The Company has a worldwide license from the University of Illinois Chicago (UIC) covering novel composition of use in therapeutic modulation of the estrogen receptor (ER) in ER+ breast cancer. TTC Oncology LLC is directed by Members,
- [In The News](https://ttconcology.com/in-the-news/) - Press Releases & Articles •TTC Oncology LLC Signs a Collaboration Agreement with Lantern Pharma | Newswire •TTC Oncology to Present at Biotech Showcase™ Digital 2021 | Business Wire •TTC-352 for Breast Cancers Resistant to Hormone Therapy Seen as Safe in Phase 1 Trial (breastcancer-news.com) •New breast cancer drug is safe and effective, can halt disease
- [Who We Are](https://ttconcology.com/who-we-are/) - Debra A. Tonetti, PhD Co-Founder & Chief Executive Officer Professor of Pharmacology, Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago. Dr. Tonetti has been a breast cancer researcher for 25 years. She was trained in the laboratory of Dr. V.C. Jordan (the “father of tamoxifen”). Her lab focuses on the etiology
- [For Investors](https://ttconcology.com/for-investors/) - The Unmet Need: High Prevalence of ER+ Breast Cancer 2.1 Million Total cases in the US, representing ~73% of all breast cancers1,2 ~10% are metastatic at diagnosis3 Up to 60% of localized cancer relapse systematically3 27% Survival Rate For metastatic ER+ breast cancer3 Problem: ­ Majority of patients with breast cancer are treated with hormonal
- [Clinical Advisory Board](https://ttconcology.com/clinical-advisory-board/) - Gini Fleming, MD Professor of Medicine, Section of Hematology and Oncology Medical Director, Gynecologic Oncology University of Chicago Medicine Dr. Fleming is an expert in breast and gynecological cancers. She has served as principal investigator or investigator on numerous phase I, II, and III clinical trials and has authored or co-authored more than 150
- [Our Product](https://ttconcology.com/our-product/) - Overview of TTC-352 Attributes ­Novel mechanism of action for hormonal therapy of breast cancer ­­Effective in heavily-pretreated ER+ breast cancer after failure of hormonal therapy and CDK4/6 inhibitors ­­Biomarker predicting activity in development (PKCa overexpression) ­­Oral capsule delivery ­­Human safety established ­­Significant key opinion leaders support for novel, non-toxic breast cancer therapy Our Solution: TTC-352 TTC
- [Contact](https://ttconcology.com/contact/) - We Want to Hear From You! Leave us a message and we’ll get back to you as soon as possible. Name Email* Message* Submit Please enable JavaScript in your browser to submit the form
- [Disease State](https://ttconcology.com/disease-state/) - ER+ Breast Cancer Estrogen Receptor-positive (ER+) breast cancer accounts for nearly three-quarters of the more than 2 million cases of breast cancer each year in the US.1,2 Hormonal therapy is a mainstay of treatment but is associated with side effects; nearly one-third of patients discontinue hormonal therapy because of toxicity.3 More than half of cases will relapse

## Categories

- [Uncategorized](https://ttconcology.com/category/uncategorized/)